| scholarly article | Q13442814 |
| P50 | author | Loretta J Nastoupil | Q87358443 |
| Christopher R Flowers | Q88175728 | ||
| Rajni Sinha | Q124061186 | ||
| P2093 | author name string | Hongzheng Zhang | |
| Turgay Ayer | |||
| Qiushi Chen | |||
| Miray Seward | |||
| P2860 | cites work | Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. | Q52024329 |
| Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. | Q53180804 | ||
| Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. | Q53218449 | ||
| Follicular lymphoma international prognostic index. | Q53289840 | ||
| Multiparameter Calibration of a Natural History Model of Cervical Cancer | Q57089398 | ||
| Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study | Q57515106 | ||
| Planning treatment of ischemic heart disease with partially observable Markov decision processes | Q60164371 | ||
| The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment | Q69033832 | ||
| The natural history of initially untreated low-grade non-Hodgkin's lymphomas | Q70817025 | ||
| Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte | Q73132182 | ||
| Long-term results with radiotherapy for Stage I-II follicular lymphomas | Q77308104 | ||
| Using engineering control principles to inform the design of adaptive interventions: a conceptual introduction | Q33266632 | ||
| A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma | Q33378233 | ||
| Flexible treatment strategies in chronic disease: clinical and research implications | Q34052842 | ||
| Improving Outcomes for Patients With Diffuse Large B-Cell Lymphoma | Q34146682 | ||
| Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. | Q34156097 | ||
| Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma | Q34598460 | ||
| Optimal Breast Biopsy Decision-Making Based on Mammographic Features and Demographic Factors | Q34670103 | ||
| Informing sequential clinical decision-making through reinforcement learning: an empirical study | Q35127824 | ||
| Customizing treatment to the patient: adaptive treatment strategies | Q35901448 | ||
| A conceptual framework for adaptive preventive interventions | Q35911597 | ||
| Constructing evidence-based treatment strategies using methods from computer science | Q35915690 | ||
| Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy | Q35979252 | ||
| Follicular lymphoma: time for a re-think? | Q36062458 | ||
| Follicular lymphoma: expanding therapeutic options. | Q36072216 | ||
| Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). | Q36211619 | ||
| Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. | Q36529941 | ||
| Controversies in follicular lymphoma: "who, what, when, where, and why?" (not necessarily in that order!). | Q36662212 | ||
| Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. | Q36910325 | ||
| Adaptive treatment strategies in chronic disease | Q36960099 | ||
| Maintenance therapy in lymphoma | Q37005070 | ||
| Follicular lymphoma: clinical features and treatment | Q37309631 | ||
| Follicular lymphoma in the United States: first report of the national LymphoCare study | Q37334742 | ||
| A decade of progress in lymphoma: advances and continuing challenges | Q37820762 | ||
| Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma | Q39431675 | ||
| No Initial Therapy for Stage III and IV Non-Hodgkin's Lymphomas of Favorable Histologic Types | Q41002229 | ||
| Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q43016599 | ||
| Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial | Q44558622 | ||
| CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma | Q45115068 | ||
| Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group | Q45229157 | ||
| Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. | Q45954449 | ||
| Improving our use and understanding of antibodies in B-cell lymphomas. | Q46200238 | ||
| Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study | Q46361336 | ||
| Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al | Q46669969 | ||
| Anti-erythroblast autoimmunity in early myelodysplastic syndromes. | Q50708515 | ||
| Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. | Q51026982 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 35-45 | |
| P577 | publication date | 2012-10-01 | |
| P1433 | published in | International journal of hematologic oncology | Q27724632 |
| P1476 | title | Initial management strategies for follicular lymphoma | |
| P478 | volume | 1 |
| Q34359297 | Lichenoid mucosal reaction to rituximab | cites work | P2860 |
Search more.